Haemonetics Co. (NYSE:HAE) Director Susan Bartlett Foote sold 16,926 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $54.19, for a total transaction of $917,219.94. Following the transaction, the director now directly owns 27,313 shares of the company’s stock, valued at $1,480,091.47. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of Haemonetics Co. (NYSE:HAE) opened at $56.06 on Thursday. The stock has a market cap of $2,877.01, a PE ratio of 33.42, a P/E/G ratio of 4.08 and a beta of 0.91. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22. Haemonetics Co. has a 1 year low of $36.44 and a 1 year high of $56.84.

Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.07. The business had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. Haemonetics had a net margin of 8.92% and a return on equity of 10.24%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the company posted $0.38 EPS. analysts expect that Haemonetics Co. will post 1.7 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2017/11/16/susan-bartlett-foote-sells-16926-shares-of-haemonetics-co-hae-stock.html.

A number of equities analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Tuesday, August 29th. BidaskClub raised shares of Haemonetics from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 8th. Morgan Stanley reaffirmed an “equal weight” rating and set a $43.00 price objective (up from $38.00) on shares of Haemonetics in a report on Friday, October 6th. Barrington Research raised shares of Haemonetics from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a report on Tuesday, August 8th. Finally, Craig Hallum reaffirmed a “hold” rating and set a $50.00 price objective (up from $40.00) on shares of Haemonetics in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $51.33.

Several institutional investors have recently made changes to their positions in HAE. UBS Asset Management Americas Inc. increased its position in shares of Haemonetics by 33.6% during the 1st quarter. UBS Asset Management Americas Inc. now owns 27,411 shares of the medical instruments supplier’s stock worth $1,112,000 after purchasing an additional 6,892 shares in the last quarter. Teachers Advisors LLC increased its position in shares of Haemonetics by 5.1% during the 1st quarter. Teachers Advisors LLC now owns 89,362 shares of the medical instruments supplier’s stock worth $3,625,000 after purchasing an additional 4,337 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Haemonetics by 7.6% during the 1st quarter. Vanguard Group Inc. now owns 4,694,325 shares of the medical instruments supplier’s stock worth $190,449,000 after purchasing an additional 332,087 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Haemonetics by 11.7% during the 1st quarter. Geode Capital Management LLC now owns 446,049 shares of the medical instruments supplier’s stock worth $18,096,000 after purchasing an additional 46,747 shares in the last quarter. Finally, State Street Corp increased its position in shares of Haemonetics by 8.3% during the 1st quarter. State Street Corp now owns 1,268,107 shares of the medical instruments supplier’s stock worth $51,449,000 after purchasing an additional 97,466 shares in the last quarter.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Receive News & Ratings for Haemonetics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Co. and related companies with MarketBeat.com's FREE daily email newsletter.